People suffering from a strange type of pancreatic cancer have been found to have witnessed an increased survival time after receiving treatment with two new tumour-inhibiting drugs. It has also been found that the progress of the tumours stalled, when patients started to consume the medications.

The two drugs, which are currently going through trials, are known as sunitib and everolimus. It has been reported that the total time of survival witnessed a drastic improvement that ranged from five to eleven months.

Apparently, the drugs are known for inhibiting those factors of the tumour that encourage the growth of pancreatic neuroendocrine tumours. The two are known for preventing the development of the condition and thus improving the length of survival.

The study was being conducted to ascertain whether the drugs were successful in providing development free survival.

All the people treated in the two separate studies were suffering from advanced neuroendocrine pancreatic tumours. Both the drugs have been found to have immense potential as both were able to provide exemplary results in the tests and had shown progress free survival for cancer patients.

Both the drugs are yet to come in the mark as they are currently going through trials. The drugs are also in the pipeline for receiving the approval of the US Food and Drug Administration.